73 Results for "

mTORC2

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "mTORC2" in MCE Product Catalog:

  • Isoforms Recommended:
4
4 Cited Publications
Cat. No.: HY-13806
CAS No.: 1251156-08-7
Purity:  99.74%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

XL388 is a highly potent and ATP-competitive mTOR inhibitor with an IC50 of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10044
CAS No.: 1144068-46-1
Purity:  99.90%
Synonyms: WYE-125132
Target:  

mTOR Apoptosis

Research Areas:  

Cancer

WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100222
CAS No.: 1429639-50-8
Purity:  98.39%
Target:  

mTOR

Research Areas:  

Cancer

CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-16962A
CAS No.: 1300118-55-1
Target:  

DNA-PK mTOR

Research Areas:  

Cancer

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-14581
CAS No.: 914913-88-5
Purity:  99.37%
Synonyms: P529
Target:  

mTOR Apoptosis

Research Areas:  

Cancer

Palomid 529 is a potent inhibitor of mTORC1 and mTORC2 complexes.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0189
CAS No.: 481-72-1
Synonyms: Rhabarberone; 3-Hydroxymethylchrysazine
Aloe emodin (Rhabarberone) is a natural hydroxyanthraquinone with antitumor activities. aloe-emodin can bind with mTORC2 and inhibit its kinase activity. Aloe emodin exerts antiproliferation effects and induces cellular apoptosis . Aloe emodin also exhibits antiviral activity that against influenza A virus [2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16956
CAS No.: 1228013-30-6
Synonyms: CC-223; ATG-008
Target:  

mTOR Apoptosis

Research Areas:  

Cancer

Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-124798
CAS No.: 2216763-38-9
Purity:  99.26%
Target:  

mTOR

Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity .
(Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-134904
CAS No.: 2382769-46-0
Purity:  95.54%
Synonyms: RM-006
Target:  

mTOR

Research Areas:  

Cancer

RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18353
CAS No.: 1207358-59-5
Target:  

mTOR

Research Areas:  

Cancer

mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15271
CAS No.: 1062161-90-3
Purity:  98.05%
Target:  

mTOR PI3K

Research Areas:  

Cancer

WYE-687 is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM. WYE-687 concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15248
CAS No.: 1207360-89-1
Purity:  98.02%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126077
CAS No.: 1567915-38-1
Purity:  99.98%
Synonyms: LXI-15029
Target:  

mTOR

Research Areas:  

Inflammation/Immunology Cancer

MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12652
CAS No.: 1101810-02-9
Purity:  99.93%
Target:  

mTOR

Research Areas:  

Cancer

AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K .
loading...
    loading...
Cat. No.: HY-137175
CAS No.: 123134-61-2
Purity:  99.60%
Target:  

mTOR

Research Areas:  

Cancer

TMBIM6 antagonist-1, a potential TMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca 2+ .
loading...
    loading...
Cat. No.: HY-134903
CAS No.: 2382768-55-8
Purity:  95.41%
Target:  

mTOR

Research Areas:  

Cancer

(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .
loading...
    loading...
Cat. No.: HY-10681R
CAS No.: 1197160-78-3
Research Areas:  

Cancer

Gedatolisib (Standard) is the analytical standard of Gedatolisib. This product is intended for research and analytical applications. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 [2].
loading...
    loading...
Cat. No.: HY-169960
Target:  

mTOR

Research Areas:  

Cancer

2DII is a potent and selective mTORC2 inhibitor. 2DII selectively binds mSin1 PH domain and decreases the expression of AKT1 phosphorylation .
loading...
    loading...
Cat. No.: HY-15247R
CAS No.: 1009298-59-2
Synonyms: AZD2014 (Standard)
Research Areas:  

Cancer

Vistusertib (Standard) is the analytical standard of Vistusertib. This product is intended for research and analytical applications. Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
loading...
    loading...
Cat. No.: HY-15174R
CAS No.: 1028385-32-1
Synonyms: BEZ235 Tosylate (Standard); NVP-BEZ 235 Tosylate (Standard)
Research Areas:  

Cancer

Dactolisib (Tosylate) (Standard) is the analytical standard of Dactolisib (Tosylate). This product is intended for research and analytical applications. Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
loading...
    loading...